The ability of E test to accurately detect fluoroquinolone resistance was compared with an agar dilution reference method. Nearly 300 isolates belonging to 26 different species (62.5% with documented ciprofioxacin resistance) were tested with ciprofloxacin, fleroxacin, levofloxacin, norfloxacin, ofloxacin, and sparfloxacin. In contrast to earlier reports, E test MIC values for pneumococci and all rapid growing aerobes were routinely higher (approximately 0.5 logi dilution step) than agar dilution results. The E test stable-gradient method also efficiently indentified fluoroquinolone-resistant subpopulations which were not detected by the reference procedure with the standard inoculum. Categorical agreement for 1710 test comparisons was approximately 90% with no very major, false-susceptible errors. We found the E test to be a valid, reproducible method for fluoroquinolone susceptibility testing that provided quantitative results and produced a conservative (1.6% false-resistant results) assessment of susceptibility of bacteria including isolates of Streptococcus pneumoniae and Pseudomonas aeruginosa to compounds in this antimicrobial class.
Introduction
Resistance to the fluoroquinolone antimicrobial agents continues to be a major concern, especially the detection of the resistant isolates by commonly utilized susceptibility testing systems (Andrews, Bradley & Wise, 1993; Holt et al., 1994) . These emerging fluoroquinolone-resistant strains appear to be multiclonal (Bauernfeind et al., 1994) and are more prevalent among some species (Jones, 1992) . Andrews et al. (1993) expressed caution in the application of the E test (AB Biodisk, Solna, Sweden) for testing fleroxacin and ofloxacin against a wide variety of bacterial species because of a perceived unacceptable rate of false susceptibility. This observation was later reinforced by Holt et al. (1994) who reported lower MICs for fleroxacin when using the E test compared to the reference agar incorporation method (NCCLS, 1993) . To address the concerns reported in these letters (Andrews et al., 1993; Holt et al., 1994) , an investigation of E test accuracy was initiated using six fluoroquinolones, 295 clinical isolates, and a reference agar dilution procedure (NCCLS, 1993 All isolates were tested simultaneously with the E test and the agar dilution procedure (NCCLS, 1993) using the manufacturer's package insert instructions and national standard documents, respectively. Six fluoroquinolones were tested: ciprofloxacin (Miles Pharmaceuticals, Inc., West Haven, CT, USA); fleroxacin (Hoffman LaRoche, Basel, Switzerland); levofloxacin and ofloxacin (Daiichi, Tokyo, Japan); norfloxacin (Merck, Rahway, NJ, USA); and sparfloxacin (Rhone-Poulenc Rorer, Collegeville, PA, USA). E test strips for each fluoroquinolone were provided by AB Biodisk.
Comparisons of interpretive agreement between methods were made using the breakpoint criteria for susceptibility published by the NCCLS (1994) or, for the as yet unmarketed drugs, published peer-reviewed reports (Sutton & Jones, 1995) . Ideally, the false-susceptible errors (compared with the reference MIC) should be reduced to <. 1.5% and total error (false-susceptible, false-resistant, intermediate) to <, 10% using an unselected, routine population of clinical isolates. Table I lists the cumulative percentage of isolates inhibited at each tested fluoroquinolone MIC for both methods. Among the 1710 (285 organisms, excluding pneumococci) comparisons of the MICs, a clear trend was observed toward higher MICs produced by the E test when using isolates more likely to exhibit resistance to the fluoroquinolones. Agar dilution MICs consistently showed higher proportions of susceptible isolates than the E test for all six fluoroquinolones tested. The differences ranged from 1% for sparfloxacin at ^1 mg/L, to 5% for fleroxacin, levofloxacin, and ofloxacin at <;2 mg/L. The test differences were more dramatic at MICs of > 4 mg/L, where the fluoroquinolone-resistant subpopulations were more easily observed as mutant colonies within the inhibition ellipse around the E test strip. The absolute interpretive or categorical agreement between the test methods for the six compounds tested ranged from 81.8% (levofloxacin) to 93.7% (norfloxacin).
Results and discussion
The distribution of all interpretive errors for the combined experiments using six fluoroquinolones are shown in Table II . The overall interpretive accord between E test and the reference agar dilution test was 89.4%. Very major, false-susceptible errors did not occur in the 1710 test comparisons. In contrast, 28 E test results (1.6%) indicated the presence of resistant, mutant subpopulations in isolates that were determined to be susceptible by the agar dilution test. Similarly, 7.6% of all E test results produced an elevated MIC that resulted in a more resistant interpretive category compared with the 'reference' method. Table III lists the 396 results obtained when testing the pneumococci (triplicate tests using the two methods for the six fluoroquinolones against ten clinical isolates and ATCC 49619). Previously described discrepancies (error/discord) with this species versus ofloxacin and fleroxacin (Andrews et al., 1993; Holt et al., 1994) were not observed in our wider investigation. However, this might be explained by the use of Mueller-Hinton agar supplemented with 5% sheep blood (NCCLS, 1993) , not IsoSensitest agar supplemented with 20 mg/L NAD and 5% horse blood; or a variation in the inoculum concentrations utilized for one or both methods. Furthermore, E test endpoint interpretation problems have been cited for the IsoSensitest agar compared to Mueller-Hinton agar when testing pneumococci (Jones, Cormican & Wanger, 1996) . Sutton & Jones (1995) .
'Absolute categorical agreement = 89.4%. Trend toward more resistant agar dilution results = 1.4%. Trend toward more resistant E test results = 7.6%. 'False-resistant, major error = 1.6% (see text). A trend toward higher E test MIC results was again observed for fleroxacin, levofloxacin, norfloxacin, ofloxacin, and sparfloxacin. Sparfloxacin E test MIC values clearly were one logj dilution step higher (E test median, 0.5 vs 0.25 mg/L for agar dilution). The reproducibility of E test results was comparable to the reference dilution method (98.5% of E test results within ±0.5 Iog2 dilutions).
Since the fluoroquinolones have become popular therapeutic agents, it becomes important to possess accurate in-vitro diagnostic tests to determine their continued clinical utility (Neu, 1992) . The rapidly emerging resistances to this class of antimicrobials are of grave concern (Jones, 1992) , and this problem appears to be widespread and multifactorial (Bauernfeind et al., 1994) . However, some species have not yet demonstrated a high likelihood of mutational fluoroquinolone resistance e.g. pneumococci, Haemophilus spp., etc. With the increasing rate of |}-lactam resistance among S. pneumoniae clinical isolates, some fluoroquinolones may assume a greater role in the therapy of selected respiratory tract infections. Therefore, accurate assessment of the potency of bioavailable drugs (levofloxacin, ofloxacin, sparfloxacin) active against pneumococci will be critical to their evolving therapeutic position, that will be concurrently challenged by increasing fluoroquinolone resistance among other species.
This investigation indicates that the E test with its use of a higher inoculum, agar-based concept may provide advantages for recognizing low frequency resistances emerging to the fluoroquinolones. This method has a particularly important role in the testing of these agents against fastidious species that may not be accurately assessed by other commonly used in-vitro test methods (disc diffusion, automated systems, commercial broth microdilution systems). In some infections additional therapeutic benefit may be achieved from measuring a precise, quantitative level of susceptibility (e.g. by the E test) that will guide effective dosing thus minimizing the emergence of resistant mutants that could remain undetected by current methods, including some reference procedures.
